TY - JOUR
T1 - Predicting trajectories of illness using RNA velocity of whole blood
AU - the PERFORM Consortium
AU - Dunican, Claire
AU - Wilson, Clare
AU - Habgood-Coote, Dominic
AU - Paterson, Suzanna
AU - Noursadeghi, Mahdad
AU - Moseki, Raymond
AU - Stek, Cari
AU - Wilkinson, Robert J.
AU - Agyeman, Philipp K.A.
AU - Beudeker, Coco R.
AU - Biesbroek, Giske
AU - von Both, Ulrich
AU - Brengel-Pesce, Karen
AU - Carrol, Enitan D.
AU - Coin, Lachlan J.M.
AU - D’Souza, Giselle
AU - De, Tisham
AU - Emonts, Marieke
AU - Fidler, Katy
AU - Fink, Colin G.
AU - van der Flier, Michiel
AU - Georgaki, Ioanna
AU - Kolberg, Laura
AU - Kolnik, Mojca
AU - Kuijpers, Taco
AU - Martinón-Torres, Federico
AU - Mommert-Tripon, Marine
AU - Nichols, Samuel
AU - Paulus, Stephane
AU - Pokorn, Marko
AU - Pollard, Andrew J.
AU - Rivero-Calle, Irene
AU - Rudzate, Aleksandra
AU - Schlapbach, Luregn J.
AU - Schweintzger, Nina A.
AU - Shen, Ching Fen
AU - Shrestha, Shrijana
AU - Tan, Chantal D.
AU - Tsolia, Maria
AU - Usuf, Effua
AU - van der Velden, Fabian
AU - Vermont, Clementien L.
AU - Voice, Marie
AU - Yeung, Shunmay
AU - Zavadska, Dace
AU - Zenz, Werner
AU - Wright, Victoria J.
AU - Levin, Michael
AU - Herberg, Jethro
AU - Wang, Shih Min
N1 - Publisher Copyright:
© 2026. The Author(s).
PY - 2026/12
Y1 - 2026/12
N2 - Transcriptomic analyses reveal the status of cells, tissues, or organisms, across states of health and disease. RNA velocity adds a temporal dimension to single cell analyses, predicting future transcriptomic and phenotypic states, based on the current spliced and unspliced mRNA of each cell. We hypothesized that RNA velocity could be adapted to predict future clinical state of individuals with acute and chronic illnesses, using their whole-blood transcriptomes. We developed VeloCD, a method for quantitative prediction of transitions in clinical state from a single time-point RNA sample. This predicts transcriptomic trajectories and future infection status in influenza A and SARS-CoV-2 controlled human infection studies, which are consistent with trajectories in naturally acquired infections. In HIV-TB coinfected individuals, VeloCD predicts the onset of immune reconstitution inflammatory syndrome. In individuals receiving biological therapy for inflammatory bowel disease, whole blood RNA velocity after the first dose of treatment indicates whether remission will be achieved by the end of the treatment course. In a multinational observational study of acutely unwell febrile children, VeloCD predicts those with greatest medical care requirements. Our results demonstrate proof-of-concept for the use of RNA velocity to predict trajectories of human diseases.
AB - Transcriptomic analyses reveal the status of cells, tissues, or organisms, across states of health and disease. RNA velocity adds a temporal dimension to single cell analyses, predicting future transcriptomic and phenotypic states, based on the current spliced and unspliced mRNA of each cell. We hypothesized that RNA velocity could be adapted to predict future clinical state of individuals with acute and chronic illnesses, using their whole-blood transcriptomes. We developed VeloCD, a method for quantitative prediction of transitions in clinical state from a single time-point RNA sample. This predicts transcriptomic trajectories and future infection status in influenza A and SARS-CoV-2 controlled human infection studies, which are consistent with trajectories in naturally acquired infections. In HIV-TB coinfected individuals, VeloCD predicts the onset of immune reconstitution inflammatory syndrome. In individuals receiving biological therapy for inflammatory bowel disease, whole blood RNA velocity after the first dose of treatment indicates whether remission will be achieved by the end of the treatment course. In a multinational observational study of acutely unwell febrile children, VeloCD predicts those with greatest medical care requirements. Our results demonstrate proof-of-concept for the use of RNA velocity to predict trajectories of human diseases.
UR - https://www.scopus.com/pages/publications/105038373312
U2 - 10.1038/s41467-026-71685-5
DO - 10.1038/s41467-026-71685-5
M3 - Article
C2 - 42091589
AN - SCOPUS:105038373312
SN - 2041-1723
VL - 17
JO - Nature communications
JF - Nature communications
IS - 1
M1 - 3652
ER -